Donna E Reece

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Hematopoietic stem cell transplantation in Hodgkin disease
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Curr Opin Oncol 14:165-70. 2002
  2. ncbi request reprint Treatment of relapsed and refractory myeloma
    Donna E Reece
    Program for Multiple Myeloma and Related Diseases, Princess Margaret Hospital, Toronto, Ontario, Canada
    Leuk Lymphoma 49:1470-85. 2008
  3. doi request reprint Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Suite 5 207, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 26:4777-83. 2008
  4. pmc Comparison of twin and autologous transplants for multiple myeloma
    Asad Bashey
    BMT Group of Georgia, Atlanta, GA, USA
    Biol Blood Marrow Transplant 14:1118-24. 2008
  5. pmc Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus
    Donna Reece
    Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON, Canada M5G 2M9
    Adv Hematol 2012:621958. 2012
  6. doi request reprint Posttransplantation maintenance therapy and optimal frontline therapy in myeloma
    Donna E Reece
    Princess Margaret Hospital, Toronto, ON, Canada
    Hematology Am Soc Hematol Educ Program 2011:197-204. 2011
  7. doi request reprint Recent trends in the management of newly diagnosed multiple myeloma
    Donna E Reece
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Curr Opin Hematol 16:306-12. 2009
  8. pmc Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Cancer Chemother Pharmacol 67:57-67. 2011
  9. pmc Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study
    Donna E Reece
    Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada
    Clin Lymphoma Myeloma Leuk 10:458-63. 2010
  10. doi request reprint Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
    Donna E Reece
    Princess Margaret Hospital, Toronto, ON, Canada
    Blood 118:865-73. 2011

Detail Information

Publications30

  1. ncbi request reprint Hematopoietic stem cell transplantation in Hodgkin disease
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Curr Opin Oncol 14:165-70. 2002
    ....
  2. ncbi request reprint Treatment of relapsed and refractory myeloma
    Donna E Reece
    Program for Multiple Myeloma and Related Diseases, Princess Margaret Hospital, Toronto, Ontario, Canada
    Leuk Lymphoma 49:1470-85. 2008
    ....
  3. doi request reprint Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Suite 5 207, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 26:4777-83. 2008
    ....
  4. pmc Comparison of twin and autologous transplants for multiple myeloma
    Asad Bashey
    BMT Group of Georgia, Atlanta, GA, USA
    Biol Blood Marrow Transplant 14:1118-24. 2008
    ..49, 95% confidence interval [CI] 0.28-0.86, P = .011). Twin transplants have a significantly lower relapse risk than autotransplants in MM, suggesting that graft composition may impact outcomes following high-dose chemotherapy...
  5. pmc Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus
    Donna Reece
    Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON, Canada M5G 2M9
    Adv Hematol 2012:621958. 2012
    ..New directions for the use of lenalidomide in RRMM are also considered...
  6. doi request reprint Posttransplantation maintenance therapy and optimal frontline therapy in myeloma
    Donna E Reece
    Princess Margaret Hospital, Toronto, ON, Canada
    Hematology Am Soc Hematol Educ Program 2011:197-204. 2011
    ..This article reviews the different regimens used with ASCT, with an emphasis on randomized trials...
  7. doi request reprint Recent trends in the management of newly diagnosed multiple myeloma
    Donna E Reece
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Curr Opin Hematol 16:306-12. 2009
    ..This review highlights the current status of different approaches to initial therapy in the era of novel drugs...
  8. pmc Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Cancer Chemother Pharmacol 67:57-67. 2011
    ..Characterize bortezomib pharmacokinetics/pharmacodynamics in relapsed myeloma patients after single and repeat intravenous administration at two doses...
  9. pmc Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study
    Donna E Reece
    Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada
    Clin Lymphoma Myeloma Leuk 10:458-63. 2010
    ..In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined...
  10. doi request reprint Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
    Donna E Reece
    Princess Margaret Hospital, Toronto, ON, Canada
    Blood 118:865-73. 2011
    ..3 mg/m² twice-weekly versus 1.6 mg/m² once-weekly dosing. Both bortezomib dose schedules represent active, well-tolerated regimens in relapsed AL amyloidosis. This study was registered at www.clinicaltrials.gov as #NCT00298766...
  11. ncbi request reprint Management of multiple myeloma: the changing landscape
    Donna E Reece
    Department of Medical Oncology Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G 2M9
    Blood Rev 21:301-14. 2007
    ..This report highlights some of the key recent findings in multiple myeloma, and describes areas for future research...
  12. ncbi request reprint Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer
    Donna E Reece
    Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Clin Breast Cancer 3:S152-7. 2003
    ..The ability to reliably produce robust immune responses after ASCT is encouraging. Further studies are required to determine if the immune response mediates an antitumor benefit in these patients...
  13. doi request reprint Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
    Donna E Reece
    Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Blood 114:1489-97. 2009
    ..2 months. Once-weekly and twice-weekly bortezomib appear generally well tolerated in relapsed AL, with promising hematologic responses. This study is registered with http://ClinicalTrials.Gov under identifier NCT00298766...
  14. ncbi request reprint Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents
    Christine I Chen
    Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
    Br J Haematol 162:483-8. 2013
    ..CNS MM is a highly aggressive disease but in our experience, long-term survival can be achieved with the combination of multi-dosing IT chemotherapy, radiation and IMiD-based therapy. ..
  15. doi request reprint Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Victor H Jimenez-Zepeda
    Princess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada
    Leuk Lymphoma 54:555-60. 2013
    ....
  16. ncbi request reprint Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival
    Victor H Jimenez-Zepeda
    Princess Margaret Hospital, Division of Medical Oncology and Hematology, Toronto, ON, Canada
    Biol Blood Marrow Transplant 18:773-9. 2012
    ..The best outcome was observed in patients whose time to progression was >24 months after first ASCT, as these patients had a subsequent PFS lasting over 1 year and an OS of almost 6 years...
  17. ncbi request reprint Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution
    Victor H Jimenez-Zepeda
    Department of Medical Oncology and Haematology, Princess Margaret Cancer Center, Toronto, ON, Canada
    Br J Haematol 164:722-8. 2014
    ..Based on this study, patients with BNP <300 pg/ml and/or normal levels of troponin-I should be considered transplant candidates. ..
  18. ncbi request reprint Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation
    Young Trieu
    Department of Medical Oncology Hematolog, Princess Margaret Hospital, University Health Network, Toronto, Ontario
    Mayo Clin Proc 80:1578-82. 2005
    ..To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT)...
  19. doi request reprint Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma
    Anca Prica
    Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Lymphoma Myeloma Leuk 13:25-31. 2013
    ..The goal of induction in younger MM patients is to improve performance status and symptoms, enabling autologous stem cell transplantation (ASCT). It is unclear whether intensification of induction regimens improves post transplant outcomes...
  20. doi request reprint Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation
    Victor H Jimenez-Zepeda
    Princess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, Ontario, Canada
    Am J Hematol 86:873-5. 2011
    ..In addition, the use of CP followed by cyclophosphamide mobilization decreases the incidence of PES leading to less morbidity and mortality rates...
  21. pmc Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    Christine Chen
    Princess Margaret Hospital, Toronto, ON, Canada
    Br J Haematol 146:164-70. 2009
    ..Primary cause of death was disease progression (10%). Safety data confirmed known AEs of lenalidomide plus dexamethasone therapy in patients with relapsed/refractory MM...
  22. pmc Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma
    Chungyee Leung-Hagesteijn
    Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada
    Cancer Cell 24:289-304. 2013
    ..These results reveal the tumor progenitor structure in MM and highlight its role in therapeutic failure...
  23. doi request reprint A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
    Lisa K Hicks
    Keenan Research Centre, Li Ka Shing Knowledge Institute and Division of Hematology Oncology, St Michael s Hospital, 30 Bond Street, Room 2065Q, Toronto, ON, Canada M5B 1W8
    Cancer Treat Rev 34:442-52. 2008
    ..However, thalidomide is associated with toxicity, particularly a significantly increased risk of VTE...
  24. ncbi request reprint A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145
    Michael J Kovacs
    NCIC Clinical Trials Group, Kingston, Ontario, Canada
    Invest New Drugs 24:529-35. 2006
    ..However, this was not reflected in clinical benefit since none of the patients had a reduction in M protein...
  25. doi request reprint Carfilzomib in multiple myeloma: gold, silver, or bronze?
    Donna E Reece
    Princess Margaret Hospital, Canada
    Blood 120:2776-7. 2012
    ..1)..
  26. doi request reprint A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Meaghan L Khan
    Hematology Oncology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Br J Haematol 156:326-33. 2012
    ..In conclusion, CyBorD demonstrated superior responses and less frequent serious toxicity but more neuropathy when compared to RD and CRD. Importantly, 80% of patients treated with modern therapeutic approaches are alive at 4years...
  27. ncbi request reprint High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study
    David H Vesole
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Mayo Clin Proc 81:880-8. 2006
    ....
  28. ncbi request reprint High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver
    Julye C Lavoie
    Leukemia Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
    Blood 106:1473-8. 2005
    ..HD-ASCT can lead to durable remissions in relapsed or refractory HL with acceptable but definite late toxicity. The occurrence of late events necessitates lifelong medical surveillance...
  29. pmc Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    Biol Blood Marrow Transplant 14:1134-40. 2008
    ..In this large cohort of patients undergoing ASCT, we found no difference in outcomes of patients with NSM compared to those with SM...
  30. ncbi request reprint Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia
    Athanasios Anagnostopoulos
    Medical Oncology, Alexandra Hospital, Athens, Greece
    Biol Blood Marrow Transplant 12:845-54. 2006
    ..Allogeneic SCT carries a much higher (40%) risk of NRM and should not be considered outside the context of a clinical trial...